hemorrhage (ICH). We performed a genome-wide association study (GWAS) of hematoma volume with the aim of identifying novel biological pathways involved in the pathophysiology of primary brain injury in ICH. Methods-We conducted a 2-stage (discovery and replication) case-only genome-wide association study in patients with ICH of European ancestry. We utilized the admission head computed tomography to calculate hematoma volume via semiautomated computer-assisted technique. After quality control and imputation, 7 million genetic variants were available for association testing with ICH volume, which was performed separately in lobar and nonlobar ICH cases using linear regression. Signals with P<5×10 −8 were pursued in replication and tested for association with admission Glasgow coma scale and 3-month post-ICH dichotomized (0-2 versus 3-6) modified Rankin Scale using ordinal and logistic regression, respectively. Results-The discovery phase included 394 ICH cases (228 lobar and 166 nonlobar) and identified 2 susceptibility loci: a genomic region on 22q13 encompassing PARVB (top single-nucleotide polymorphism rs9614326: β, 1.84; SE, 0.32; P=4.4×10 ; heterogeneity, P=0.16) but not for 22q13 (P=0.49). In multivariable analysis, rs11655160 was also associated with lower admission Glasgow coma scale (odds ratio, 0.17; P=0.004) and increased risk of poor 3-month modified Rankin Scale (odds ratio, 1.94; P=0.045). Conclusions-We identified 17p12 as a novel susceptibility risk locus for hematoma volume, clinical severity, and functional outcome in nonlobar ICH. Replication in other ethnicities and follow-up translational studies are needed to elucidate the mechanism mediating the observed association.
H ematoma volume is an established neuroimaging biomarker of primary injury in spontaneous intracerebral hemorrhage (ICH). It is a powerful predictor of clinical outcome 1 and strongly correlates with markers of clinical and radiological severity, including admission Glasgow coma scale (aGCS), presence of contrast extravasation in computed tomographic (CT) angiography (termed the spot sign), and hematoma expansion. [2] [3] [4] Importantly, this predictive power applies to both lobar and nonlobar hemorrhages, making ICH volume a useful tool regardless of the specific biology underlying the brain bleed. 3, 5 Beyond its predictive potential, ICH volume is easy to calculate and widely available in everyday clinical practice because almost all patients with ICH undergo a head CT on admission to the hospital. 6 In combination, these characteristics make hematoma volume an ideal radiological marker to study the mechanisms of primary injury that determine severity and outcome in ICH.
Inherited genetic variation plays an important role in ICH. Heritability estimates indicate that 40% of the variation in ICH risk can be attributed to rare and common mutations. [7] [8] [9] Additionally, several monogenic diseases that follow a Mendelian pattern of inheritance manifest clinically through ICH, including familial cerebral amyloid angiopathy and COL4A1-related ICH. 10 Large association studies have also identified common mutations in APOE, PMF1, and COL4A1/COL4A2 [10] [11] [12] that increase ICH risk with incomplete penetrance. Furthermore, mutations in genes related to blood pressure and lipid levels-2 physiological pathways known to influence ICH occurrence-also modify the risk of ICH. [13] [14] [15] Recent studies indicate that the role of genetic variation extends beyond risk to also influence clinical severity, radiological severity, and functional outcome in ICH. For lobar ICH, the APOE epsilon 2 allele associates with a 5-mL increase in mean ICH volume, resulting in a 50% increase in risk of poor outcome. 16 For deep ICH, the cumulative burden of hypertension-related mutations associates with a 2.7-mL increase in mean ICH volume, resulting in a 71% increase in risk of poor outcome.
14 Despite these findings, genome-wide association studies (GWAS) focused on ICH volume are lacking. Given the unique potential of this radiological marker and the valuable information provided by genome-wide scans, we conducted a GWAS of ICH volume, as measured on the first head CT scan on admission to the hospital. Our hypothesis is that a substantial proportion of the variation observed in ICH volume can be attributed to genetic variation and that this genetic contribution translates into concrete genetic risk loci that influence not only the size of the hematoma but also clinical severity.
Methods

Study Design and Participating Cohorts
This work adheres to the Transparency and Openness Promotion Guidelines. The full set of genome-wide association results of this study will be available through the Cerebrovascular Disease Knowledge Portal (http://www.cerebrovascularportal.org). 17 The individual level data of this study are available through 2 different publicly available resources: the American Heart Association Precision Medicine Platform (http://precision.heart.org/) and the Database of Genotypes and Phenotypes (http://www.ncbi.nlm.nih. gov/gap). We utilized a case-only study design that included discovery and replication stages. The qualifying event for all cohorts was the occurrence of a nontraumatic, spontaneous ICH. ICH cases included in the discovery phase were subjects of European ancestry enrolled in the GOCHA study (Genetics of Cerebral Hemorrhage With Anticoagulation)-a multicenter study conducted in the United States. 13 ICH cases included in the replication phase were subjects of European ancestry enrolled in the Hospital del Mar Intracerebral Hemorrhage study (Barcelona, Spain), 18 Vall d'Hebron Hospital ICH study (Barcelona, Spain), 19 and Lund Stroke Register study (Lund, Sweden). 20 Because of their limited sample sizes, data from the 3 European studies utilized for replication were pooled for genomic quality control, imputation, and association testing. Included studies had approval from the local institutional review board or ethics committee at each participating institution. Informed consent was either obtained from patients or their legally authorized representatives.
Cases
Subjects were enrolled in participating studies according to predefined criteria. Included subjects were aged >55 years (GOCHA) or >18 years (European studies) and had a diagnosis of spontaneous, nontraumatic ICH. Spontaneous ICH was defined as a new and acute neurological deficit with compatible neuroimaging findings showing the presence of intraparenchymal bleeding. Patients with hemorrhage resulting from anticoagulation, trauma, conversion of an ischemic infarct, rupture of a vascular malformation or aneurysm, or brain tumor were excluded.
Ascertainment of ICH Volume
For all subjects, ICH volume in the first available CT on admission was centrally read at the Massachusetts General Hospital using Analyze Direct 11.0 software-a semiautomated computer-assisted technique with excellent interrater reliability (intraventricular bleeding was not included in volume calculations). 21 In accordance with the known biology of the disease, ICH cases were classified as lobar or nonlobar based on the location of the bleed within the brain. Hematomas originating in the cerebral cortex or cortical-subcortical junction were classified as lobar, whereas hematomas originating in the thalamus, internal capsule, basal ganglia, deep periventricular white matter, cerebellum, or brain stem were classified as nonlobar. Bleeds involving both deep and lobar territories were defined as mixed ICH, and these individuals were not eligible for inclusion in our analysis.
Clinical Data
Demographics, clinical variables, and medical history were collected through retrospective review of hospital charts. We identified comorbidities, medications, laboratory values, and aGCS. 22 The modified Rankin Scale (mRS) 23 was assessed through follow-up telephone calls 3 months after the index ICH.
14,24
Ascertainment of Genotypes
Genotyping
Cases were genotyped using Illumina HumanHap610-Quad (San Diego, CA), as part of a previous published study. 11 Standardized prespecified quality control procedures were implemented separately for the discovery and replication datasets. 25 These filters excluded singlenucleotide polymorphisms (SNPs) with genotype call rate <0.95, significant differential missingness across bins of ICH volume, deviation from Hardy-Weinberg equilibrium (P<1×10 −6 ), or minor allele frequency <0.01. At the sample level, quality control excluded individuals with a genotype call rate of <95%, who had inconsistency between self-reported and genotypic sex, who had an inferred firstor second-degree relative in the sample identified based on pairwise allele sharing estimates (estimated genome proportion shared identical by descent; π>0.1875), and who had extreme genome-wide heterozygosity F statistics.
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Population Stratification
Following quality control procedures, principal-component analysis 26 was implemented to account for population structure.
Imputation
Imputation was performed separately in the discovery and replication datasets using IMPUTE2 V2.2 27 and 1000 Genomes 28 integrated reference panels (phase I interim release in National Center for Biotechnology Information build 37). Postimputation filters excluded imputed SNPs with minor allele frequency <0.01, IMPUTE2 information score <0.7, confidence score <0.9, and missing estimates in association testing for ≥1 studies.
Statistical Analysis
Descriptive Statistics
Discrete data are presented as count (percentages) and continuous data as mean (SD) or median (interquartile range [IQR]) as appropriate.
Association Testing for Risk Loci Discovery
Genome-wide association analyses were computed separately for lobar ICH and nonlobar ICH volume. We chose this approach given the known differences in biology across locations, 29 which were confirmed by a previous GWAS of ICH risk. 11 Following standard practices in the field, ICH volume was natural log-transformed to approximate normality. [30] [31] [32] Analyses were computed separately for the discovery and replication phases via linear regression, assuming additive genetic effects (1 degree-of-freedom additive trend test) and adjusting for age, sex, and the first 4 principal components. Following standard practices in the field, these covariates were added to the regression models to improve model fitting and enhance statistical precision, not to adjust for confounding. Quantile-quantile plots were utilized to assess systematic inflation in association results resulting from population stratification or other systematic causes of bias. A Bonferroni-corrected significance threshold of 5×10 −8 , adjusting for 1 million independent genetic loci across the human genome, was used to declare statistical significance.
Meta-Analysis
Results from the discovery and replication stages were pooled in meta-analysis using an inverse-variance weighed, fixed-effects approach. Heterogeneity across effect estimates was evaluated using I 2 values.
Association Testing to Evaluate Clinical Significance
We used ordinal multivariable logistic regression to test for association between the identified genetic risk loci and aGCS, as well as multivariable logistic regression to test for association between these same loci and a dichotomized version (0-2 versus 3-6) of 3-month postbleed mRS, as done previously. 33, 34 All these models were adjusted for multiple confounders (age, sex, hypertension, diabetes mellitus, antiplatelet use, and principal components 1-4).
Annotation
Variants identified at genetic risk loci were evaluated for gene expression in cis using publicly available resources. SNPs with P<1×10 −5 were assessed in 4 publicly available eQTL databases: SCAN-SNP and copy number variation (CNV) annotation database, the National Center for Biotechnology Information Genotype-Tissue Expression eQTL Browser, 35 the Pritchard Laboratory UChicago eQTL Browser, 36 and mRNA by SNP Browser, v1.0.1. 37 The positions of SNPs in ICH volume-associated loci were overlapped with DNase I hot spot regions from the Encyclopedia of DNA Elements Project that mark generalized chromatin accessibility, mapped for each of 125 diverse cell lines and tissues. 38 In addition, ICH volume-associated SNPs were analyzed for overlap with Encyclopedia of DNA Elements data, including transcription factor motifs, using RegulomeDB. 39 
Copy Number Variant Analysis
Because one of the identified loci overlaid multiple copy number variants, PennCNV was used to ascertain this type of variant in a 62-Mb region that began at the start of the CNV farthest away from the locus of interest in one direction and finished at the end of the CNV that was the farthest away from this same locus in the opposite direction.
Statistical analyses were completed using PLINK, 40 SAS 9.3, and PennCNV. 41 
Results
After excluding subjects based on principal components analysis (n=43) and quality control procedures (n=16), 394 ICH cases (mean age, 73 [SD, 10]; women, 47%) were included in the discovery stage (Table 1) . Lobar ICH cases comprised 58% (n=228) of the discovery cohort. The median ICH volumes, as measured in the first available CT scan on admission to the hospital, were 50 (IQR, 43 mL) and 27 mL (IQR, 34 mL) for lobar and nonlobar hemorrhages, respectively. After preimputation quality control procedures, imputation to 1000 Genomes reference panels, and postimputation quality control filters, a total of 7 567 631 and 7 569 876 SNPs were available for association testing in the discovery sample for lobar and nonlobar ICH, respectively. Quantile-quantile plots showed no significant inflation in association results (Figures I and II in the online-only Data Supplement).
Genome-Wide Association Results
We identified 2 genome-wide significant susceptibility loci for ICH volume, 1 for lobar and 1 for nonlobar ICH (Table 2) . In lobar ICH, several SNPs in a genomic region of 22q13 encompassing PARVB were significantly associated with ICH volume (Figures 1A and 2A ; Table I in the online-only Data Supplement). For rs9614326, the strongest correlated SNP, each additional C allele was associated with a mean decrease of 6.3 mL in ICH volume (tested allele frequency, 3%; β, 1.58; SE, 0.29; P=4.5×10 −8 ). In nonlobar ICH, several SNPs in an intergenic region of 17p12 were significantly associated with ICH volume (Figure 1B ). For the strongest associated SNP, rs11655160, each additional A allele was associated with a mean decrease of 2.6 mL in ICH volume (tested allele frequency, 24%; β, 0.95; SE, 0.17; P=4.3×10 −8 ).
Replication of SNPs Associated With ICH Volume
The replication stage confirmed the association between rs11655160 in 17p12 and ICH volume in nonlobar ICH. This stage comprised 240 ICH cases (mean age, 74 [SD, 12] ; women, 43%), of which 71 (30%) corresponded to lobar ICH. Median ICH volume was 68 (IQR, 92 mL) and 28 mL (IQR, 38 mL) for lobar and nonlobar ICH, respectively, in the replication sample ( Table 1) . The preimputation quality control procedures, imputation pipeline, and postimputation quality control filters were similar to those utilized in the discovery phase. For 17p12 in nonlobar ICH, each additional A allele of rs11655160 was associated with a 1.7-mL decrease in mean ICH volume (tested allele frequency, 26%; β, 0.52; SE, 0.25; P=0.036). In a meta-analysis across the replication and discovery stages, the same rs11655160 allele was associated with a 6.6-mL decrease in mean ICH volume (β, 0.82; SE, 0.14; P=2.5×10 −9 ), with no significant heterogeneity detected across effect estimates (heterogeneity, P=0.16). In lobar ICH, no significant association was found between 22q13 and ICH volume (tested SNP rs9614326: β, 0.4; SE, 0.66; P=0.49; Table 2 ).
Clinical Impact of ICH Volume-Associated Loci in the Discovery Sample
The identified genetic risk locus at 17p12 was associated with both admission clinical status and functional outcome in the discovery data set (Table 3) . On admission to the hospital, median aGCS was 7 (IQR, 7-15). Ninety days after the ICH, 132 (40%) patients had died, 147 (26%) had an mRS of 0 to 2, and 109 (33.6%) had an mRS of 3 to 6. After adjustment for multiple potential confounders, each additional G allele of rs11655160 was associated with better clinical status on admission, as measured by the aGCS (β, 0.17; SE, 0.60; P=0.004), and better functional outcome, as measured by a dichotomized version of the 3-month post-ICH mRS (odds ratio, 1.94; SE, 0.33; P=0.045).
Locus Mapping and Regional Functional Annotation
The susceptibility risk locus for nonlobar ICH volume identified in 17p12 encompasses a narrow 32-kb intergenic region ( Figure 2B ). This locus has no reported associations with other traits. A total of 20 SNPs within this locus achieved P<5×10 −5 (Table II in the online-only Data Supplement). Two of these variants were directly genotyped in the Illumina 660 BeadChip utilized for genotyping. 17p12 does not contain coding genes or DNAse I hypersensitivity sites. rs11655160 is greatly enriched for copy number variation, overlapping 154 different CNVs ( Figure III in the onlineonly Data Supplement; Table III in the online-only Data Supplement) that cover a 62-Mb region around rs11655160. These CNVs included duplications, insertions, inversions, intrachromosomal breakpoints, and short tandem repeats of different sizes, from single base pair alterations to large chromosomal abnormalities spanning. Neither the presence of any CNV at this locus nor the total sum of CNVs called by PennCNV was associated with ICH volume, although power and genotyping considerations limit the conclusiveness of this analysis.
Discussion
In this GWAS of hematoma volume in spontaneous, nontraumatic ICH, we evaluated genetic, radiological, and clinical data on 634 well-phenotyped cases of European ancestry across discovery and independent replication phases. We identified 2 novel genome-wide significant susceptibility risk loci for ICH volume: 17p12 for nonlobar ICH and 22q13 for lobar ICH. The association at 17p12 was replicated in an independent data set of patients with ICH without evidence of effect heterogeneity across the discovery and replication phases. Further supporting our findings, this same locus correlated with admission clinical status, as measured by the aGCS, and functional outcome 3 months after the stroke, as evaluated by the mRS. Although the 17p12 locus corresponds to an intergenic region, it overlays numerous CNVs of various sizes and types.
Our study provides new evidence on the role of common genetic variation in hematoma formation in spontaneous ICH. Beyond well-known Mendelian conditions that manifest with ICH, recent candidate gene and GWAS studies identified APOE, COL4A1/COL4A2, SLC22A44, and PMF1 as susceptibility loci for ICH risk. 10, 16, 42 The identification of these susceptibility loci for risk hinted that genetic variation could also influence ICH volume, as converging lines of evidence indicate that biological processes related to risk also influence volume in ICH. One possible Age, y; mean (±SD) 73 (10) 72 (10) 74 (11) 74 (12) 74 (11) 74 (13) Women, n (%) 194 (47) 81 (49) 112 (48) 102 (43) 66 (39) 36 (51) Baseline ICH volume, mean (±SD) 39 (41) 27 (34) 50 (43) 40 (62) 28 (38) 68 (92) Baseline ICH volume, median (IQR) 23 (51) 13 (27) 36 (64) 16 (43) 12 (31) 
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explanation for this phenomenon is the cascade hypothesis, which posits that the volume of hematoma is influenced by the severity of the small vessel disease that initially caused the hemorrhage. 43 According to this model, the final size of the hematoma depends on the additional bleeding contributed by the rupture of previously diseased small vessels located in the periphery of the artery from which the ICH originated. This line of thinking was supported by candidate gene studies that showed that APOE variants related to risk also associated with an increase in the mean volume of the ICH. 16 The present study identified a genome-wide significant locus for ICH volume at 17p12. In line with results yielded by prior GWAS of ICH risk, this susceptibility locus was location specific, exerting its effect on nonlobar hemorrhages only. Importantly, the top SNP within this locus, rs11655160, was also associated with clinical status on admission and functional outcome 3 months after the bleed. The identified locus mapped to an intergenic region that has not been associated with stroke or other phenotypes by previous genomewide studies. The most important finding of our functional characterization efforts is that the locus of interest is greatly affected by copy number variation, as shown by the 154 CNVs identified in this genomic region. Neither single-CNV nor aggregate-CNV analyses yielded significant associations between copy number variation and ICH volume; however, these findings are greatly limited by our sample size. Despite this negative preliminary analysis, the number and variety of CNVs found at this locus highlight a possible mechanism mediating the observed association.
To further understand the interpretability of our results, we hypothesize that the signal found may be tagging the pathophysiological process of the small vessel disease. To explore this possibility, given the close relation between white matter hyperintensity and cerebral small vessel burden, we looked at the effect of the top SNP rs11655160 on this trait. Three main GWAS have been performed to identify genetic associations with this neuroimaging marker. [44] [45] [46] Among the top SNPs found associated with white matter hyperintensities, none mapped on the 17p12 region.
A second genome-wide significant locus, located at 22q13, was identified for lobar ICH. This locus encompasses PARVB-a gene that codes for β-parvin, a member of the parvin family of actin-binding proteins, which plays an important role in cytoskeleton organization and cell adhesion. 47 These proteins are associated with focal contacts and contain calponin homology domains that bind to actin filaments. Unfortunately, we were not able to replicate the association between 22q13 and ICH volume in lobar hemorrhages.
Our study has a number of limitations that are worthwhile mentioning. Patients with massive brain hemorrhages 
may have died before reaching the hospital, or immediately after admission to the emergency department, and were thus excluded from the present analysis. Second, some misclassification between lobar and nonlobar ICH could have occurred, although the reliability of the utilized classification approach has proven to be excellent in prior studies. 48 Our data do not include magnetic resonance imaging. Although magnetic resonance imaging is less used in the acute setting of stroke, it can provide additional information and a better classification of the underlying pathology compared with an analysis that is CT based (cerebral amyloid angiopathy versus small vessel disease burden). Possible directions for future research efforts may involve a better classification of ICH based also on features coming from advanced neuroimaging data. Finally, our sample size is small for GWAS studies and mostly composed of individuals of European ancestry. This raises the possibility of false-positive associations and precludes a complete fine mapping of the linkage disequilibrium structure at the locus. Larger sample sizes will be crucial to further validate our findings and provide transethnic replications.
Summary
In summary, we report the first GWAS of hematoma volume in spontaneous, nontraumatic ICH. We identified a novel susceptibility locus for nonlobar ICH (chromosomal region 17p12) that influences radiological severity, clinical severity, and functional outcome in ICH that occurs in deep regions of the brain. Our results indicate that the influence of common genetic variation in ICH extends beyond risk to also modify the severity and outcome of this condition. Although the specific biological mechanism underlying the observed association remains to be elucidated, the presence of numerous CNVs colocalizing with the identified locus suggests that this specific type of mutation could be responsible for the observed changes in ICH volume. Ongoing genetic studies with larger sample sizes will likely answer this question. 
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